{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"The sum of 6 pleural thickness measurements is added to sum of the longest diameters of all non-pleural measurable lesions. The resulting values are evaluated using RECIST.","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"AZD2171"}],"paramType":"NUMBER","populationDescription":"Eligible patients who received any amount of AZD2171","reportingStatus":"POSTED","timeFrame":"Disease assessments for response were performed every 8 weeks as long as the patient remained on protocol treatment, up to 5 years.","title":"Objective Response Rate Per Modified RECIST for Pleural Tumors","type":"SECONDARY","unitOfMeasure":"percentage of participants"}